acitretin / Generic mfg. - LARVOL DELTA

Treatment of Isolated Nail Psoriasis with JAK Inhibitor Tofacitinib: A Case Report. (PubMed, Clin Cosmet Investig Dermatol) - "We present a 39-year-old female with a 6-year history of refractory isolated nail psoriasis, previously unresponsive to itraconazole, acitretin, topical antifungals, and corticosteroids. The present report offers preliminary evidence supporting the efficacy of a JAK inhibitor in the treatment of refractory isolated nail psoriasis. Large-scale controlled trials are warranted to confirm long-term safety and clinical efficacy."

Journal • Dermatology • Immunology • Infectious Disease • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • JAK1 • JAK3

Reply to 'Caution in interpreting retrospective comparisons of acitretin and bexarotene in mycosis fungoides'. (PubMed, Br J Dermatol) - No abstract available

Journal • Retrospective data • Cutaneous T-cell Lymphoma • Dermatology • Mycosis Fungoides • Oncology

Tumoral Chromoblastomycosis Caused by Fonsecaea monophora: A Treatment Challenge. (PubMed, Int J Dermatol) - No abstract available

Journal • Oncology

Coexistence of Erythrodermic Psoriasis and Bullous Pemphigoid: A Case Report. (PubMed, Clin Cosmet Investig Dermatol) - "The patient was treated with oral acitretin combined with high-potency topical halometasone cream, no new bullae occurred subsequently...This rare case of BP secondary to EP in a young adult underscores that clinicians should maintain high suspicion for BP when tense bullae develop de novo in patients with EP. Timely performance of histopathology, perilesional direct immunofluorescence, and pemphigoid-targeted serological testing is critical for establishing a definitive diagnosis."

Journal • Bullous Pemphigoid • Dermatology • Dermatopathology • Immunology • Psoriasis

Caution in Interpreting Retrospective Comparisons of Acitretin and Bexarotene in Mycosis Fungoides. (PubMed, Br J Dermatol) - No abstract available

Journal • Retrospective data • Cutaneous T-cell Lymphoma • Dermatology • Mycosis Fungoides • Oncology

Serum neopterin level in psoriatic patients treated with acitretin or narrowband ultraviolet B or both (EADV 2026) - No abstract available

Clinical • Immunology

Acitretin versus Isotretinoin in Pustular Psoriasis: A Real-World Comparative Study (EADV 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Dermatology • Immunology • Psoriasis • Pustular Psoriasis

Acitretin-Induced Sixth Nerve Palsy in a Child with Generalized Pustular Psoriasis (EADV 2026) - No abstract available

Clinical • Dermatology • Immunology • Psoriasis • Pustular Psoriasis

Hand eczema and its subtypes (EADV 2026) - "Finally, a stepped-care management approach will be outlined, from prevention and patient education to topical therapy (topical corticosteroids and calcineurin inhibitors), before advancing to therapies for refractory cases (phototherapy, alitretinoin, oral corticosteroids, cyclosporin, azathioprine, methotrexate, acitretin) and the topical pan-JAK inhibitor delgocitinib. Investigative work-up and exposure identification: participants will focus on patient history and diagnostic tools (patch testing, prick testing) to detect relevant triggers. Application of therapeutic algorithm: attendees will master a stepwise treatment protocol, progressing from basic therapy (emollients / skin care, exposure reduction) to topical and systemic therapy, focusing on treatment choice through clinical cases and gaining confidence of using targeted therapies like delgocitinib."

Contact Dermatitis • Dental Disorders • Dermatology • Immunology • Urticaria

Topical sirolimus for the treatment of verrucous epidermal nevus associated with an HRAS mosaic mutation: a case report. (PubMed, Front Med (Lausanne)) - "The child showed poor response to conventional treatments, including surgical excision, topical retinoic acid cream, and oral acitretin. However, after treatment with topical 0.5% (w/w) sirolimus ointment, the child's skin lesions showed reduced area, thinning, improved pigmentation, and decreased roughness, and no local or systemic adverse reactions were observed during the 6-month treatment period. This case suggests that topical sirolimus may represent a potentially effective therapeutic option for patients with verrucous epidermal nevus who are refractory to conventional therapy."

Journal • Rare Diseases • HRAS

Acitretin shows promising potential in Alzheimer's disease: retinoid-driven modulation of amyloid processing, neuroinflammation, and translational prospects. (PubMed, Inflammopharmacology) - "Importantly, biomarker-based clinical studies demonstrate increased cerebrospinal fluid APP-α following acitretin administration, confirming central target engagement in humans. Although definitive clinical efficacy remains to be established, acitretin's pleiotropic mechanism, established pharmacological profile, and biomarker responsiveness position it as a promising repurposed candidate within biomarker-guided and combination-based therapeutic strategies for AD."

Journal • Review • Alzheimer's Disease • CNS Disorders • Inflammation • ADAM10 • APP • IL6 • TNFA

Biologic Therapy for Pityriasis Rubra Pilaris: A Single Center Retrospective Case Series. (PubMed, Int J Dermatol) - No abstract available

Journal • Retrospective data

Clinical practice guideline for psoriasis management in Latin America. (PubMed, An Bras Dermatol) - "This guideline offers an actionable framework for comprehensive psoriasis care in Latin America, balancing best available evidence with regional constraints to support equitable, patient-centered implementation in routine clinical practice."

Clinical guideline • Journal • Dermatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Oncology • Pediatrics • Psoriasis • Pulmonary Disease • Pustular Psoriasis • Respiratory Diseases • Tuberculosis

Acitretin-inspired medicinal chemistry for Alzheimer's disease: A biomarker-gated central nervous system (CNS) discovery framework. (PubMed, Drug Discov Ther) - "The resulting concept is an evidence-gated scaffold-redesign strategy: future work may test whether retinoid-ADAM10-APP signaling can be retained while systemic retinoid burden and metabolite persistence are reduced. Further progression would require convergence of unbound CNS exposure, bounded sAPPα modulation, and acceptable safety within the same concentration range."

Biomarker • Journal • Alzheimer's Disease • CNS Disorders • Dermatology • Immunology • Psoriasis • ADAM10 • APP

Oral Acitretin Combined with Topical 0.1% Tretinoin Cream for Facial Basal Cell Carcinoma in an Elderly Patient: A Case Report. (PubMed, Biologics) - "During the treatment course, only mild adverse events, including skin dryness and cheilitis, were observed, and no significant laboratory abnormalities occurred. This case suggests that oral acitretin combined with topical 0.1% tretinoin cream may represent a feasible and well-tolerated nonsurgical option for selected elderly patients with facial BCC, and no recurrence was observed during the 4-month follow-up."

Journal • Basal Cell Carcinoma • Non-melanoma Skin Cancer • Oncology • Skin Cancer • Skin Nodular Basal Cell Carcinoma

Systemic Treatment of Psoriasis: Current Evidence on Efficacy and Safety. (PubMed, J Dermatol) - "Older conventional systemic agents, such as cyclosporin, acitretin, or methotrexate, remain useful in selected settings, especially when treatment options are limited by cost or availability, when short-term disease control is needed, or when the patient prefers these treatments...Biologics targeting TNF-α or anti-IL-12/23p40 ustekinumab have established the biologic treatment era, and remain clinically relevant, especially for patients having psoriatic arthritis or prioritizing long-term safety...Targeted oral therapies increase options for patients who prefer non-injectable treatment; established or emerging agents include apremilast, deucravacitinib, icotrokinra, zasocitinib, envudeucitinib, and orismilast. Emerging IL-17-directed agents, including sonelokimab and izokibep, may further refine pathway targeting. Selection of treatment should be decided dependently on the completeness of skin clearance achieved, speed and duration of responses, effectiveness on..."

Journal • Review • Candidiasis • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL17A • TNFA

Marked improvement of isolated acrodermatitis continua of hallopeau with upadacitinib: a case report and literature review. (PubMed, Front Med (Lausanne)) - "The disease was refractory to topical corticosteroids, systemic antibiotics, acitretin, and 1 year of secukinumab therapy. No adverse or unanticipated events were observed during follow-up. This case highlights the potential role of JAK1 inhibition as an effective therapeutic strategy for refractory ACH and supports further investigation into JAK-targeted therapies in pustular psoriasis spectrum disorders."

Journal • Dermatitis • Dermatology • Immunology • Inflammation • Psoriasis • Pustular Psoriasis • JAK1

Combination Therapy with Upadacitinib and Acitretin in Recalcitrant Darier Disease: A Case Report. (PubMed, Acta Derm Venereol) - No abstract available

Journal

Successful treatment of Galli-Galli Disease with dupilumab and acitretin combination therapy. (PubMed, Dermatol Online J) - No abstract available

Journal

Multimodal management of eruptive squamous atypia in a patient with chronic immunosuppression. (PubMed, Dermatol Online J) - No abstract available

Journal

A Rash Decision: Refractory Erythroderma as an Atypical Presentation of Hypocomplementaemic Urticarial Vasculitis (BAD 2026) - "In this context, he was commenced on treatment for psoriasis with acitretin 25 mg daily and weekly methotrexate, without clinical improvement...Repeat biopsies during a second admission were interpreted as psoriasis with superimposed tinea incognito, prompting treatment with oral itraconazole. Given refractory disease, guselkumab was also commenced...In terms of further management, the patient was commenced on dapsone, titrated to 100 mg daily, in combination with oral prednisolone 10 mg daily. This resulted in marked improvement in pruritus and gradual resolution of the cutaneous findings. Steroid-sparing strategies are ongoing, with omalizumab under consideration."

CNS Disorders • Dermatology • Dermatopathology • Immunology • Pruritus • Psoriasis • Sleep Disorder • Urticaria • Vasculitis

Icotrokinra (Icotyde) for psoriasis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Dermatology • Immunology • Psoriasis

3 Cases of Biologic Associated Interstitial Lung Disease (BAD 2026) - "She had previously been treated unsuccessfully with adalimumab (March 2019 to June 2020), secukinumab (June 2020 to October 2020), ixekizumab (October 2020 to January 2023 and May 2023 to January 2024) and ustekinumab (February 2023 to May 2023)...She was previously treated with acitretin (September 2006 to March 2007), methotrexate (April 2007 to June 2019), ustekinumab (August 2018 to June 2019), adalimumab (June 2019 to December 2024) and secukinumab (December 2024 to present)...She was treated with adalimumab (November 2021 to April 2023), guselkumab (April 2023 to April 2024) and ixekizumab (April 2024 to present)...Our cases highlight this contentious issue. Abstracts i163"

Clinical • Breast Cancer • Chronic Obstructive Pulmonary Disease • Immunology • Interstitial Lung Disease • Psoriasis • Pulmonary Disease • Respiratory Diseases • Solid Tumor

A retrospective cohort study on the efficacy and safety comparison of tofacitinib citrate tablets combined with acitretin capsules and acitretin capsules alone in the treatment of primary cutaneous amyloidosis (ChiCTR) - P4 | N=56 | Completed | Sponsor: The First Affiliated Hospital of Army Medical University; The First Affiliated Hospital of Army Medical University

New P4 trial • Amyloidosis • Dermatopathology

Comparative Efficacy of Apremilast and Acitretin in Moderate-to-Severe Hidradenitis Suppurativa (clinicaltrials.gov) - P4 | N=70 | Completed | Sponsor: Hayat Abad Medical Complex, Peshawar

New P4 trial • Dermatology • Hidradenitis Suppurativa • Immunology